Alix Alderman serves as Vice President of Regulatory Affairs and Global Market Access at PellePharm. Prior to joining PellePharm, Alix led all regulatory aspects of global development and strategy for the rare bone disease programs at Ultragenyx as Senior Director of Regulatory Affairs. Prior to Ultragenyx, she served as Director of Global Product Strategy and Global Regulatory Lead at Abbott/AbbVie. Previously, she held numerous positions of increasing responsibility at Amylin and InterMune, including regulatory affairs leadership for Amylin’s orphan drug, obesity and pramlintide research, development and commercial franchise. Alix is a member of The Organisation for Professionals in Regulatory Affairs (TOPRA) and served for many years on the TOPRA Board of Directors. She earned her bachelor’s degree in exercise physiology from the University of California at Davis.